Receive The Newest Study Notifications

Study Met All Primary and Secondary Endpoints  PL-8177 is a Melanocortin Receptor 1 Agonist Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with...

Perficient, Inc. (NASDAQ: PRFT) (“Perficient”), the leading digital transformation consulting firm serving Global 2000® and other large enterprise customers throughout North America, today announced it has successfully implemented Oracle’s Siebel Clinical Trial...

A currently approved epileptic drug to treat seizures has been modified by a University of Colorado Anschutz Medical Campus professor and is currently being used in a clinical trial in Australia for medically refractory epilepsy. Tom Anchordoquy, Professor at the CU...

Cognizant  CTSH, +0.83% has introduced Cognizant Protocol Creator, a SaaS collaboration product that automates the development of clinical trial protocol documentation. A first for the life sciences industry, Protocol Creator enables clinical teams to create and...

New feature helps clinical trial research sites and sponsors more accurately and efficiently achieve IRS tax compliance while maintaining confidentiality and privacy Greenphire, the global leader in financial software for clinical trials, announced today that it has...

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug-resistant infections, today announced the initiation of the ATTACK (Acinetobacter Treatment Trial Against Colistin)...

A large clinical trial "RELIEVE-IBS-D" for patients with diarrhoea predominant IBS (IBS-D) included in the National Institute for Health Research portfolio has started recruitment in England. The trial is using some of the latest research technologies to collect data...

Small NIH clinical trial conducted in partnership with AstraZeneca. A drug approved to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders called hypereosinophilic syndromes (HES) in whom other treatments were...

Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, N.Y. evaluating Hemispherx’ experimental drug Ampligen® (rintatolimod), a dsRNA TLR3 agonist, in combination with Merck’s...

BriaCell Therapeutics and Incyte have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA0012, an...

Oral presentation highlights investigator case reports showing early signs of activity of Tedopi® in patients with non-small cell lung cancer in third-line treatment after checkpoint inhibitor failure Poster presentation shows new preclinical mechanistic data of BI...

Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at community-based oncology practices, announced today that its Trials-in-Progress poster titled “SYNERGY-AI: Artificial...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its...

New Protocol Creator Software Brings Treatments to Market Faster  Cognizant (Nasdaq: CTSH) has introduced Cognizant Protocol Creator, a SaaS collaboration product that automates the development of clinical trial protocol documentation. A first for the life sciences...

Investigational vaccine designed to provide broad, durable protection from flu. The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in...

Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a phase 1bclinical trial of a new experimental glioblastoma vaccine developed by Jefferson Health and Imvax, show the treatment...

Florence, the company that advances clinical trials with software, welcomes healthcare IT industry veteran Steve Chamberlain to its advisory network. Chamberlain, who also made an undisclosed investment in Florence, brings experience driving growth at disruptive...

In Collaboration with Colorado State University College of Veterinary Medicine and Biomedical Sciences, and Downing Center for Pain Management HempMy Pet™, a vertically integrated Colorado Hemp company that grows medicinal hemp and produces CBD-infused pet products,...

Topline data from ORCA-1 trial expected in the Second Quarter of 2019 Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced...

Amylyx Pharmaceuticals, Inc., in collaboration with the Alzheimer’s Association, the Alzheimer’s Drug Discovery Foundation (ADDF) and the Cure Alzheimer’s Fund, today announced the dosing of its first patients in a recently expanded Phase 2 clinical trial (PEGASUS) to...